SCHEMBL7054031

SCHEMBL7054031

CCSc1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.48
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
NOS3 P29474 2/20 0.44
NOS1 P29475 2/20 0.44
NOS2 P35228 2/20 0.44
BLM P54132 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
DAO P14920 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
SLC6A4 P31645 9/20 0.42
MAOA P21397 1/20 0.42
SLC6A2 P23975 2/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13799440 0.83 AR (0.50) PTGDR2ALDH1A1LMNANOS3NOS1
SCHEMBL28367599 0.81 HRH3 (0.46) ALDH1A1CYP1A2CYP3A4CYP2C19DAO
SCHEMBL17688592 0.80 SLC6A4 (0.46) PTGDR2ALDH1A1SLC6A4MAOANPC1
SCHEMBL346860 0.80 SLC6A4 (0.56) ALDH1A1MAPK1SLC6A4MAOANPC1
SCHEMBL2376871 0.79 HRH3 (0.45) ALDH1A1CYP1A2CYP3A4CYP2C19DAO
SCHEMBL13220841 0.79 ALDH1A1 (0.55) ALDH1A1LMNACYP1A2CYP3A4CYP2C19
SCHEMBL28551761 0.79 HRH3 (0.45) ALDH1A1CYP1A2CYP3A4CYP2C19DAO
SCHEMBL28205464 0.78 KDM1A (0.46) PTGDR2ALDH1A1LMNANPSR1HRH3
SCHEMBL13724698 0.77 HRH3 (0.44) PTGDR2ALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL13724723 0.77 PTPN1 (0.44) ALDH1A1CYP1A2CYP3A4CYP2C19DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2501236-B1 N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer PLEXXIKON INC (US) 2017-03-29 EP disclosed
US-20160368930-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-12-22 US disclosed
EP-1304325-A1 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368930-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER KRAS, HRAS, NRAS PTGDR2 3452/4885ALDH1A1 2792/4885LMNA 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.